APPROACH/TARGET
INDICATION
DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
SNS-301
ASPH; HPV- specific E6/E7
1st Line Head & Neck Cancer in combination with pembrolizumab
- PD-1 blockade has been approved for several years in the treatment of advanced SCCHN after platinum-containing chemotherapy, but the objective response rate has been reported to be modest at 13% to 18% with progression-free survival (PFS) of two months and overall survival (OS) of eight months.
- The addition of SNS-301 has the potential to enhance PD-1 blockade activity.
- We also intend to use an ImmunoPhage cocktail targeting the E6/E7 antigens of HPV, in combination with SNS-301, in HPV-positive patients in our ongoing trial of SNS-301.
Head & Neck Cancer Neoadjuvant in combination with durvalumab
- We will evaluate the safety and efficacy of SNS-301 in combination with durvalumab for patients with locally advanced, resectable SCCHN in the neoadjuvant setting.
SNS-401
Cocktail with MCPyV
Merkel Cell Carcinoma
- First custom MCC vaccine consisting of Merkel Cell Polyoma Virus (MCPyV) epitopes together with other patient-specific antigens.
- MCC is a rare but highly aggressive neuroendocrine carcinoma of the skin in which MCPyV infection and chronic exposure to ultraviolet radiation are key risk factors.
- Although systemic PD-1/PD-L1 inhibition therapy is associated with a high overall response rate, prolonged durable responses, and good tolerability in advanced-stage MCC, refractory PD-1/PD-L1 inhibitor disease remains a significant unmet medical need with an aggressive clinical course.
SNS-VISTA
VISTA
Solid Tumors
- VISTA is an immunoregulatory receptor and is highly expressed on various immune system cells including neutrophils, monocytes, macrophages, basophils, and dendritic cells.
- VISTA blockade appears to dramatically modulate the tumor microenvironment toward a state that favors an immune system response, resulting in improved T cell effector function and anti-tumor activity.
Nanobodies & Antibodies
Various
Discovery & validation of multiple antibodies & nanobodies utilizing ImmunoPhage platform
- Proprietary nanobodies, derived from alpacas, are antibody-like structures that consist of a single monomeric variable domain located on the heavy chain.
- We are developing nanobodies targeted to immune checkpoints and other immune-stimulatory molecules that can be packaged into the phage as immunomodulatory payloads to enhance immunogenicity.
![](/wp-content/plugins/pipeliner/ImmunoPhage-Icon.png)
![](/wp-content/plugins/pipeliner/Antibody-Icon.png)